AMPE Raises Capital After Mixed Optina Data; Pre-Market Declines Could Persist
Ampio Pharmaceuticals (NASDAQ:AMPE) announced this morning that it has priced its 4.6M share equity offering at $3.25 per share ,with Aegis Capital Corp. and Fordham Financial Management, Inc. acting as joint book runners. AMPE recently reported results of its Phase II trial for Optina, a treatment for diabetic macular edema, in which it was unclear whether or not the primary endpoint in the study was met. Instead of addressing the trial’s pre-specified primary endpoint, the company chose to report efficacy in certain patients by correlating their body mass index (BMI) with different doses of the drug, despite some inconsistencies in the subpopulations. As such, there is no way to tell whether these small subpopulations demonstrated that the drug will show efficacy in a larger clinical study, or that the data reported was the result of the company finding a cause and effect that was favorable by chance. Additionally, adverse events in the study including peripheral edema, psoriasis, and worsening depression may have been treatment related, and therefore, pose questions about Optina’s ability to get to the market. So with Ampio raising capital off of these questionable results, investors may question the quality of this company and its prospects. Expect the shares to remain weak today, with the possibility to trade back to their lows of the year.
Earned income that exceeded $200,000 (or $300,000 together with a spouse) in each of the prior two years, and reasonably expects the same for the current year,
OR
Has a net worth over $1 million, either alone or together with a spouse (excluding the value of the person’s primary residence).
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.
Four
Five
×
Please Confirm Your Email!
We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox and click the verification link.
If you cannot find it, be sure to check you "SPAM" or click "RESEND EMAIL" below.
Forgot your password?
Enter the email address associated with your account and we'll send you details on how to reset your password.
Reset Link Emailed
A email with details on resetting your password has been sent.
Your question is submitted. Our moderators are reviewing the question and will approve it shortly.
Enter the email address associated with your account and we'll send you details shortly.
You're trying to access some of PropThink's Members-Only Content.
You can sign up for a FREE PropThink membership, unlocking significantly more of PropThink’s features, by clicking here. All it takes is an email address.
Better yet, try PropThink Premium. Click here to read more about the features of PropThink Premium, and get 50% off your first month!